In xenografts, only tumour cells expressing human CD47 will bind human CD47-targeting reagents, potentially achieving higher concentrations of antibody in the tumour than in syngeneic models where both malignant and normal cells can bind CD47, creating an “antigen sink” [24,30]. The gene discussed is CD47; the disease is neoplasm.